Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-11-26 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于召开2025年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会) for investors. It specifies the date, time, location, and participation method for the meeting, which is a typical investor presentation or earnings call event. The document does not contain actual financial statements or detailed financial analysis but rather invites investors to attend and ask questions. It is not the earnings release itself, nor a full interim report, but an announcement of an investor meeting focused on quarterly results. Therefore, the best classification is Investor Presentation (IP). The document length is short and it is clearly an announcement of a meeting, not the meeting transcript or report itself, so it is not a Call Transcript (CT) or Interim Report (IR).
2025-11-26 Chinese
天士力第九届董事会第15次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from the company 天士力医药集团股份有限公司. It reports on the 15th meeting of the 9th board, held on October 23, 2025. The key points include approval of the 2025 third quarter report and an organizational structure adjustment. The document states that the detailed 2025 third quarter report is published on the Shanghai Stock Exchange website, indicating this document itself is not the full quarterly report but an announcement of board decisions including approval of that report. The document length is short (662 characters), and it serves as a formal announcement of board resolutions rather than containing substantive financial data or the full report. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and organizational changes.
2025-10-24 Chinese
天士力2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 Third Quarter Report" of TianShiLi Pharmaceutical Group Co., Ltd. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and shareholder information for the third quarter period ending September 30, 2025. The report explicitly states it is unaudited and covers a quarterly period (three months). The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-24 Chinese
天士力关于公司2025年前三季度主要经营数据的公告
Regulatory Filings Classification · 95% confidence The document is titled as an announcement of the company's main operating data for the first three quarters of 2025. It provides summarized financial data such as revenue, cost, and gross margin by industry and treatment field for the period January to September 2025. The document explicitly states that the data is unaudited and is a disclosure in compliance with Shanghai Stock Exchange regulatory guidelines for quarterly report disclosure. The document length is short (1599 characters) and it does not contain full financial statements or detailed analysis, but rather a summary of key operating data. It is not a full Interim/Quarterly Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is also not an Earnings Release (ER) since it is more detailed than key highlights but less than a full report. The document is an official announcement of main operating data for the first three quarters, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure that does not fit other categories. Therefore, the classification is RNS with high confidence.
2025-10-24 Chinese
天士力关于公司药品温经汤颗粒获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company regarding the receipt of a drug registration certificate from the national drug regulatory authority. It details the drug's basic information, registration approval, and risk warnings related to production and sales. The document is short (914 characters) and serves as a formal public announcement of a regulatory approval event, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category, which is covered by Regulatory Filings (RNS).
2025-10-13 Chinese
内蒙古建中律师事务所关于天士力医药集团股份有限公司2025年第五次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of a specific shareholders' meeting (the 2025 fifth extraordinary general meeting) of a company. It references the convening, attendance, voting procedures, and results of the shareholders' meeting, confirming their compliance with laws and company bylaws. This type of document is not a report of financial results, nor an announcement of voting results, but a legal opinion on the meeting's conduct. It is not a full Annual Report, Audit Report, or any financial report. It is also not a Proxy Solicitation or Voting Results announcement. Given the nature of the document as a legal opinion on a shareholders' meeting, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2025-10-10 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.